Studies of the biogenic amine transporters. 13. identification of "agonist" and "antagonist" allosteric modulators of amphetamine-induced dopamine release

Journal of Pharmacology and Experimental Therapeutics

Volumn 329, Issue 2, 2009, Pages 718-728

  Rothman, Richard B ^a   Dersch, Christina M ^a   Ananthan, Subramaniam ^b   Partilla, John S ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 3,4 METHYLENEDIOXYAMPHETAMINE; AMINE; AMPHETAMINE; COCAINE; DOPAMINE; DOPAMINE TRANSPORTER; DOPAMINE UPTAKE INHIBITOR; SEROTONIN; SORI 20040; SORI 20041; SORI 9804; TRITIUM; UNCLASSIFIED DRUG; DEXAMPHETAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT;

ALLOSTERISM; AMINE TRANSPORT; ANIMAL TISSUE; ARTICLE; BRAIN SYNAPTOSOME; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DRUG IDENTIFICATION; DRUG MECHANISM; INHIBITION KINETICS; KINETICS; MALE; NERVE ENDING; NONHUMAN; NORADRENERGIC NERVE; PRIORITY JOURNAL; RAT; SEROTONINERGIC NERVE; ANIMAL; BRAIN; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECT; METABOLISM; SECRETION; TRANSPORT AT THE CELLULAR LEVEL;

ALLOSTERIC REGULATION; ANIMALS; BIOLOGICAL TRANSPORT; BRAIN; DEXTROAMPHETAMINE; DOPAMINE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MOLECULAR STRUCTURE; RATS;

EID: 65649121112     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.149088     Document Type: Article

References (34)

1. 3H]Cocaine labels a binding site associated with the serotonin transporter in guinea pig brain: allosteric modulation by paroxetine. Neurochem Res 17:1275-1283.
2. Andersson A and Marcusson J (1989) Inhibition and dissociation of [3H]-paroxetine binding to human platelets. Neuropsychobiology 22:135-140.
3. Chang AS and Chang SM (1999) Nongenomic steroidal modulation of high-affinity serotonin transport. Biochim Biophys Acta 1417:157-166.
4. Chen F, Larsen MB, Neubauer HA, Sanchez C, Plenge P, and Wiborg O (2005) Characterization of an allosteric citalopram-binding site at the serotonin transporter. J Neurochem 92:21-28.
5. Chen N and Reith ME (2000) Structure and function of the dopamine transporter. Eur J Pharmacol 405:329-339.
6. Christopoulos A and Kenakin T (2002) G protein-coupled receptor allosterism and complexing. Pharmacol Rev 54:323-374.
7. Ferrer JV and Javitch JA (1998) Cocaine alters the accessibility of endogenous cysteines in putative extracellular and intracellular loops of the human dopamine transporter. Proc Natl Acad Sci U S A 95:9238-9243.
8. Gether U, Andersen PH, Larsson OM, and Schousboe A (2006) Neurotransmitter transporters: molecular function of important drug targets. Trends Pharmacol Sci 27:375-383.
9. Goodwin JS, Larson GA, Swant J, Sen N, Javitch JA, Zahniser NR, De Felice LJ, and Khoshbouei H (2009) Amphetamine and methamphetamine differentially affect dopamine transporters in vitro and in vivo. J Biol Chem 284:2978-2989.
10. Gorman JM and Kent JM (1999) SSRIs and SMRIs: broad spectrum of efficacy beyond major depression. J Clin Psychiatry 60 (Suppl 4):33-38.
11. Grabowski J, Shearer J, Merrill J, and Negus SS (2004) Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence. Addict Behav 29:1439-1464.
12. Khoshbouei H, Sen N, Guptaroy B, Johnson L, Lund D, Gnegy ME, Galli A, and Javitch JA (2004) N-Terminal phosphorylation of the dopamine transporter is required for amphetamine-induced efflux. PLoS Biol 2:E78.
13. Nandi A, Dersch CM, Kulshrestha M, Ananthan S, and Rothman RB (2004) Identification and characterization of a novel allosteric modulator (SoRI-6238) of the serotonin transporter. Synapse 53:176-183.
14. Nightingale B, Dersch CM, Boos TL, Greiner E, Calhoun WJ, Jacobson AE, Rice KC, and Rothman RB (2005) Studies of the biogenic amine transporters. XI. Identification of a 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl) piperazine (GBR12909) analog that allosteric ally modulates the serotonin transporter. J Pharmacol Exp Ther 314:906-915.
15. Pariser JJ, Partilla JS, Dersch CM, Ananthan S, and Rothman RB (2008) Studies of the biogenic amine transporters. 12. Identification of novel partial inhibitors of l amphetamine-induced dopamine release. J Pharmacol Exp Ther 326:286-295.
16. Pifl C, Wolf A, Rebernik P, Reither H, and Berger ML (2009) Zinc regulates the ; dopamine transporter in a membrane potential and chloride dependent manner. Neuropharmacology 56:531-540.
17. Reith ME, Berfíeld JL, Wang LC, Ferrer JV, and Javitch JA (2001) The uptake i inhibitors cocaine and benztropine differentially alter the conformation of the human dopamine transporter. J Biol Chem 276:29012-29018.
18. Reith ME, de Costa B, Rice KC, and Jacobson AE (1992) Evidence for mutually í exclusive binding of cocaine, BTCP, GBR 12935, and dopamine to the dopamine transporter. Eur J Pharmacol 227:417-425.
19. Roth BL, Lopez E, Beischel S, Westkaemper RB, and Evans JM (2004) Screening the receptorome to discover the molecular targets for plant-derived psychoactive compounds: a novel approach for CNS drug discovery. Pharmacol Ther 102:99-110.
20. Rothman RB and Baumann MH (2006) Therapeutic potential of monoamine transporter substrates. Curr Top Med Chem 6:1845-1859.
21. Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, and Partilla JS (2001) Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39:32-41.
22. Rothman RB, Baumann MH, Prisinzano TE, and Newman AH (2008) Dopamine transport inhibitors based on GBR12909 and benztropine as potential medications to treat cocaine addiction. Biochem Pharmacol 75:2-16.
23. Rothman RB, Blough BE, and Baumann MH (2006) Dual dopamine-5-HT releasers: potential treatment agents for cocaine addiction. Trends Pharmacol Sci 27:612-618.
24. Rothman RB, Dersch CM, Carroll FI, and Ananthan S (2002) Studies of the biogenic amine transporters. VIII: Identification of a novel partial inhibitor of dopamine uptake and dopamine transporter binding. Synapse 43:268-274.
25. 3H]l,3-di(2-tolyl)guanidine of two high affinity binding sites in guinea pig brain: evidence for allosteric regulation by calcium channel antagonists and pseu do allosteric modulation by u ligands. Mol Pharmacol 39:222-232.
26. Rothman RB, Vu N, Partilla JS, Roth BL, Hufeisen SJ, Compton-Toth BA, Birkes J, Young R, and Glennon RA (2003) In vitro characterization of ephedrine-related stereoisomers at biogenic amine transporters and the receptorome reveals selective actions as norepinephrine transporter substrates. J Pharmacol Exp Ther 307:138-145.
27. Rudnick G and Clark J (1993) From synapse to vesicle: the reuptake and storage of biogenic amine neurotransmitters. Biochim Biophys Acta 1144:249-263.
28. Sanchez C (2006) Allosteric modulation of monoamine transporters - new drug targets in depression. Drug Discov Today Ther Strategies 3:483-488.
29. Scholze P, Nørregaard L, Singer EA, Freissmuth M, Gether U, and Sitte HH (2002) The role of zinc ions in reverse transport mediated by monoamine transporters. J Biol Chem 277:21505-21513.
30. Schwartz TW and Hoist B (2007) Allosteric enhancers, allosteric agonists and agoallosteric modulators: where do they bind and how do they act? Trends Pharmacol Sci 28:366-373.
31. +1. J Pharmacol Exp Ther 290:1363-1368.
32. Sur C, Betz H, and Schloss P (1998) Distinct effects of imipramine on 5-hydroxytryptamine uptake mediated by the recombinant rat serotonin transporter SERT1. J Neurochem 70:2545-2553.
33. Zhu J and Hexum TD (1992) Characterization of cocaine-sensitive dopamine uptake in PC12 cells. Neurochem Int 21:521-526.
34. Zohar J and Westenberg HG (2000) Anxiety disorders: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl 403:39-49.